- Home
- SVRA vs CDNA Comparison
SVRA vs CDNA Comparison
Compare SVRA & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRA | CDNA |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SVRA | CDNA |
|---|---|---|
| Price | $6.02 | $20.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $7.33 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 1.5M | 723.7K |
| Earning Date | 11-12-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $357,998,000.00 |
| Revenue This Year | N/A | $14.47 |
| Revenue Next Year | N/A | $11.35 |
| P/E Ratio | ★ N/A | $16.81 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $1.89 | $10.96 |
| 52 Week High | $7.01 | $25.55 |
Technical Indicators
Market Signals| Indicator | SVRA | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 56.46 |
| Support Level | $5.60 | $19.48 |
| Resistance Level | $6.49 | $21.49 |
| Average True Range (ATR) | 0.29 | 1.18 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 53.52 | 76.57 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.